Mindaugas Jievaltas - Concepedia

Author

Mindaugas Jievaltas

Lithuanian University of Health Sciences ORCID

Also Known As

Jievaltas M, M Jievaltas, M. Jievaltas, Mindaugas JIEVALTAS, Mindaugas Jievaltas

156

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Lithuanian University of Health Sciences National Cancer Institute Carolina Urologic Research Center Pauls Stradiņš Clinical University Hospital Vilnius University

About

Mindaugas Jievaltas is an author at Lithuanian University of Health Sciences specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	116
2	Public Health	1	1	12
3	Metabolism	1	1	18
4	Nephrology	1	1	18
5	Pathology	1	1	22

Mindaugas Jievaltas

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, New England Journal of Medicine	2019	890
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, New England Journal of Medicine	2020	341
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial Fred Saad, Egils Vjaters, Neal D. Shore, Journal of Clinical Oncology	2024	102
Evaluation of LRINEC Scale Feasibility for Predicting Outcomes of Fournier Gangrene Marius Kinčius, Titas Telksnys, Darius Trumbeckas, Surgical Infections	2016	47
Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Journal of Clinical Oncology Cancer ManagementPharmacotherapyOverall SurvivalGynecology OncologyPre-clinical Pharmacology	2020	46
Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial Matthew R. Smith, Neal D. Shore, Teuvo L.J. Tammela, European Journal of Cancer	2021	35
Significance of Time Until PSA Recurrence After Radical Prostatectomy Without Neo- or Adjuvant Treatment to Clinical Progression and Cancer-Related Death in High-Risk Prostate Cancer Patients Žilvinas Venclovas, Mindaugas Jievaltas, Daimantas Milonas Frontiers in Oncology	2019	27
Does Illness Perception Explain Quality of Life of Patients With Prostate Cancer? Aušra Mickevičienė, Giedrius Vanagas, Mindaugas Jievaltas, Medicina	2013	23
Factors influencing renal graft survival: 7-Year experience of a single center Rūta Auglienė, Eglė Dalinkevičienė, Vytautas Kuzminskis, Medicina	2017	23
Lichen sclerosus et atrophicus in pediatric and adult male patients with congenital and acquired phimosis Daiva Jasaitienė, Skaidra Valiukevičienė, Daiva Vaitkienė, Medicina Atrophic DiseaseVulvar DiseasesAdult Male PatientsChronic InflammatoryLichen	2008	22

Page 1